1991年 · 第07卷第06期

63 streptozotocin induced diabetic rats were divided into 3 Groups fed with different amounts of protein diets-Group 1 (7%) Group 2 (20%) and Group 3 (40%) respectively for 2 months. The ratio of right kidney weight/body weight (RKW/BW), 24 hours urinary protein excretion (UPE), CCr, mean glomerular diameter (MGD), the colloidal iron staining (CIS) on surface of foot processes of glomerular epithelial cells and nuclear acid content in renal tissue were observed by the end of the experiment. The results showed that RKW/BW in Group 1 (4.14±0.34) was decreased compared with those in Group 2 (5.22±0.30) and Group 3 (5.39±0.79), P<0.05. UPE in Group 1 (8.58±3.09 mg) was reduced significantly compared with in Group 2 (20.39±5.9mg) and Group 3 (29.41±4.6 mg), p<0.01. The MGD in Group 3 (114.35±1.65 um) was increased compared with those in Group 2 (107.75±5.85 um) and Group 1 (103.75±5.71 um), P<0.05. The nuclear acid content in Group 3 (6.1±0.4 mg) was increased compared with those in Group 2 (4.9±0.5mg) and Group 1 (4.7±0.1 mg), P<0.05. The ratio of RNA/DNA in Group 3 (0.98±0.09) was increased markedly compared with those in Group 2 (0.82±0.03) and Group 1 (0.67±0.03), P<0.001. But Ccr in diabetic rats fed with different diets showed no significant difference. Finally, it was found that fusion of foot processes and decreased CIS were intensified by increased dietary protein content. The present findings suggested that restriction of protein intake was able to retard the progresses of diabetic nephropathy.

In order to investigate the apolipoprotein alterations in patients with chronic renal failure, we measured the serum levels of ApoAI, ApoAII and ApoB by immunoturbidimetry in 31 uremic patients, including 23 dialysed and 8 patients under usual conservative therapy, and compared the results with the values obtained in a group of 97 age-matched control subjects.

Results showed that the serum concentrations of ApoAI, ApoAII and ApoB were 1.00±0.27g/L, 0.19±0.07g/L, 0.79±0.24g/L, respectively in uremic patients group. They were all significantly decreased in comparision with the values of 1.75±0.41g/L, 0.38±0.09g/L, 1.08±0.40g/L, respectively in matched controls (P<0.001 in each). The ratio of ApoAI/ApoB was markedly decreased in uremic patients (P<0.001).

These results indicate that the significant decrease in levels of ApoAI and ApoAII is characteristic apolipoprotein alterations in patients with chronic renal failure. Although ApoB is reduced the ratio of ApoAI/ApoB is still lower than normal. It is proposed that the decrease of ApoAI and ApoAII could be considered as a possible important mechanism for accelerated atherosclerosis in patients with chronic renal failure.